The global kinase inhibitors market reached $28.1 billion in 2010 and
nearly $29.1 billion in 2011. The market is expected to reach $40.2 billion by
2016, a compound annual growth rate (CAGR) of 6.7%.
The emerging markets segment for kinase inhibitors reached $2.9 billion in
2010 and $4.1 billion in 2011. The market is expected to reach $8.4 billion by
2016, a CAGR of 15.2%.
The emerging markets segment for antibody kinase inhibitors reached $1.8
billion in 2010 and $2.1 billion in 2011. The market is expected to reach $4.3
billion by 2016, a CAGR of 15.2%.
SUMMARY FIGURE
GLOBAL REVENUE OF KINASE INHIBITORS MARKET, 2009-2016
($ MILLIONS)
Source: BCC Research
STUDY OBJECTIVES
BCC's goal in conducting this study is to provide an overview of the current
and future characteristics of the global market for kinase inhibitors. The key
objective is to present a comprehensive analysis and the future direction of
kinase inhibitors to provide an important tool for the usage of these types of
enzyme inhibitors.
This report explores present and future strategies within the kinase
inhibitors market, which includes tyrosine inhibitors, multi-target kinase
inhibitors, serine/ threonine inhibitors and monoclonal antibody kinase
inhibitors. The direction of the market, its setbacks and the needs of the
market are discussed in this report. The classifications, comparisons and
usage of these types of enzyme inhibitors are also examined in the report.
A detailed analysis of the kinase inhibitors industry structure has been
conducted. Revenues are broken down by region. Sales figures are estimated for
the five-year period from 2011 through 2016.
Applications for kinase inhibitors are also discussed separately in the
report, with emphasis on the usage of the inhibitors in therapeutic categories
and various disease sectors. The report also covers significant patents and a
summary of patents awarded in each category.
SCOPE OF THE STUDY
The scope of this study encompasses kinase inhibitors in pharmaceutical and
biotechnology markets. BCC analyzes each market and its applications,
regulatory environment, technology, market projections and market share.
Technological issues include the latest trends and developments. The emerging
market for enzyme inhibitors includes India, China, Japan, South Korea,
Taiwan, Canada, Africa, Australia and New Zealand and others countries.
METHODOLOGY
Both primary and secondary research methodologies were used in preparing this
study. BCC conducted a comprehensive literature search, which included
technical newsletters and journals and many other sources. Data were collected
through interviews and correspondence with manufacturers of enzyme inhibitors
and technical experts. Projections were based on estimates such as the current
number of end users, potential end users, mergers and acquisitions, and market
trends.
INFORMATION SOURCES
Many companies active in the kinase inhibitor industry were surveyed to obtain
data for this study. Included were manufacturers and end users of kinase
inhibitors in therapeutic categories and various disease sectors industries.
Data were gathered from various industry sources. BCC spoke with officials
within the industry, consulted newsletters, company literature, product
literature, and a host of technical articles, journals, indexes, and
abstracts. Exhaustive investigations of databases by key terminology were
conducted. In addition, data were compiled from current financial, trade and
government sources.
ABOUT THE AUTHOR
A team of professionals in the biotechnology industry carried out this study.
The project manager is Shalini S. Dewan, who holds a master's degree in
pharmaceutical chemistry and has over 14 years of industry experience. Among
the research topics she has covered are studies on compounds of potential
pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was
awarded a Gold Medal by the Prime Minister of India for her work and has
worked with top companies in India and in the U.S.
Table of Contents
Table of Contents
Kinase Inhibitors: Global Markets -- Focus on Emerging Markets
Chapter - 1: INTRODUCTION - Complimentary
STUDY OBJECTIVES
REASONS FOR DOING THIS STUDY
INTENDED AUDIENCE
SCOPE OF THE STUDY
METHODOLOGY
INFORMATION SOURCES
ABOUT THE AUTHOR
RELATED BCC RESEARCH REPORTS
BCC ONLINE SERVICES
DISCLAIMER
Chapter - 2: SUMMARY
Table Summary: GLOBAL REVENUE OF KINASE INHIBITORS MARKET, THROUGH 2016
Figure Summary: GLOBAL REVENUE OF KINASE INHIBITORS MARKET, 2009-2016
Chapter - 3: OVERVIEW
DEFINITIONS
ENZYME INHIBITORS
KINASE INHIBITORS
CLASSIFICATION BY TYPES OF AMINO ACID PHOSPHORYLATION
CLASSIFICATION BY SITE OF ACTION
Chapter - 4: REGULATORY ASPECTS
MARKET LEADERS AND THEIR PRODUCTS FOR KINASE INHIBITORS
Table 13: LEADING MANUFACTURERS AND SUPPLIERS OF RECEPTOR TYROSINE
KINASE INHIBITORS
Table 14: LEADING MANUFACTURERS AND SUPPLIERS OF NON-RECEPTOR TYROSINE
KINASE INHIBITORS
Table 15: LEADING MANUFACTURERS AND SUPPLIERS OF MULTI-TARGET TYROSINE
KINASE INHIBITORS
Table 16: LEADING MANUFACTURERS AND SUPPLIERS OF SERINE AND THREONINE
KINASE INHIBITORS
Table 17: LEADING MANUFACTURERS AND SUPPLIERS OF ANTIBODY KINASE
INHIBITORS
Chapter - 5: NEW DEVELOPMENTS
(RECEPTOR) TYROSINE KINASE INHIBITORS (TKIS)
(NON-RECEPTOR) TYROSINE KINASE INHIBITORS (TKIS)
MULTIKINASE INHIBITORS
SERINE/THREONINE KINASE INHIBITOR
OTHER KINASE INHIBITOR PRODUCTS UNDER DEVELOPMENT
Table 18: CLINICAL TRIALS IN EPIDERMAL GROWTH FACTOR RECEPTOR
Table 19: CLINICAL TRIALS IN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2
(HER2) TKIS
Figure 12: GLOBAL MARKET FOR KINASE INHIBITORS BY APPLICATIONS, 2009-2016
Figure 13: GLOBAL MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC
AGENTS, 2009-2016
Figure 14: GLOBAL MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,
2009-2016
Figure 15: GLOBAL MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR
DEGENERATION, 2009-2016
Figure 16: GLOBAL MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS, 2010
Figure 17: EMERGING MARKETS FOR KINASE INHIBITORS, 2009-2016
Figure 18: EMERGING MARKETS FOR TYROSINE KINASE INHIBITORS, 2009-2016
Figure 19: EMERGING MARKETS FOR RECEPTOR TYROSINE KINASE INHIBITORS,
2009-2016
Figure 20: EMERGING MARKETS FOR MULTIKINASE TYROSINE KINASE INHIBITORS,
2009-2016
Figure 21: EMERGING MARKETS FOR SERINE/THREONINE KINASE INHIBITOR,
2009-2016
Figure 22: EMERGING MARKETS FOR MONOCLONAL ANTIBODY KINASE INHIBITORS,
2009-2016
Figure 23: SHARE OF RECEPTOR TYROSINE KINASE INHIBITOR MANUFACTURERS IN
EMERGING MARKETS, 2010
Figure 24: SHARES OF MULTI-TARGET KINASE INHIBITOR MANUFACTURERS IN
EMERGING MARKETS, 2010
Figure 25: SHARES OF SERINE/THREONINE KINASE INHIBITOR MANUFACTURERS IN
EMERGING MARKETS, 2010
Figure 26: SHARES OF SERINE/THREONINE KINASE INHIBITOR MANUFACTURERS IN
EMERGING MARKETS, 2010
Figure 27: EMERGING MARKETS FOR KINASE INHIBITORS BY APPLICATION, 2009-2016
Figure 28: EMERGING MARKETS FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC
AGENTS, 2009-2016
Figure 29: EMERGING MARKETS FOR KINASE INHIBITORS USED AS
IMMUNOSUPPRESSANTS, 2009-2016
Figure 30: EMERGING MARKETS FOR KINASE INHIBITORS USED IN AGE-RELATED
MACULAR DEGENERATION, 2009-2016
Figure 31: SHARE OF KINASE INHIBITORS IN EMERGING MARKETS BY APPLICATION,
2010
Figure 32: NUMBER OF PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012
Figure 33: NUMBER OF PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012
Figure 34: PATENTS BY CATEGORY FOR KINASE INHIBITORS 2008 TO END OF
FEBRUARY 2012
Figure 35: PATENTS BY TYPE FOR TYROSINE KINASE INHIBITORS 2008 TO END OF
FEBRUARY 2012
Figure 36: PATENTS BY TYPE FOR SERINE/THREONINE KINASE INHIBITORS, 2008 TO
END OF FEBRUARY 2012
Figure 37: NUMBER OF U.S. PATENTS BY COUNTRY FOR KINASE INHIBITORS, 2008
TO END OF FEBRUARY 2012
Figure 38: PATENT SHARES BY COUNTRY FOR KINASE INHIBITORS, 2010 - 2012
Figure 39: PATENT SHARES BY COUNTRY FOR KINASE INHIBITORS, 2008-2012
Kinase Inhibitors: Global Markets -- Focus on Emerging Markets published by BCC Research in June 30, 2012. This report consists of 119 Pages and the price starts from US $ 4400.
